Epstein-Barr Virus and the Human Leukocyte Antigen Complex.

IF 3.1 Q2 MICROBIOLOGY Current Clinical Microbiology Reports Pub Date : 2019-09-01 Epub Date: 2019-07-08 DOI:10.1007/s40588-019-00120-9

Qingxue Li, Jeffrey I Cohen

{"title":"Epstein-Barr Virus and the Human Leukocyte Antigen Complex.","authors":"Qingxue Li, Jeffrey I Cohen","doi":"10.1007/s40588-019-00120-9","DOIUrl":null,"url":null,"abstract":"Purpose: While most adults are infected Epstein-Barr virus (EBV), 3-5% remain uninfected. The human leukocyte antigen (HLA) complex, which controls many pathogens, may influence infection and disease associated with EBV.Recent findings: Numerous EBV proteins and miRNAs down-regulate HLA class I and II expression on the cell surface. HLA class II functions as a receptor for EBV entry into B cells. Specific HLA class II alleles correlate with the susceptibility of B cells to EBV infection in vitro and with EBV seropositivity or seronegativity of humans. HLA class I polymorphisms correlate with development and severity of EBV infectious mononucleosis and with the risk of several virus-associated malignancies including nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease.Significance: These findings indicate that while EBV has evolved to use MHC class II as a receptor for virus entry, polymorphisms in MHC class II and class I influence virus infection and disease.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"6 3","pages":"175-181"},"PeriodicalIF":3.1000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-019-00120-9","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Clinical Microbiology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40588-019-00120-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 12

Abstract

Purpose: While most adults are infected Epstein-Barr virus (EBV), 3-5% remain uninfected. The human leukocyte antigen (HLA) complex, which controls many pathogens, may influence infection and disease associated with EBV.

Recent findings: Numerous EBV proteins and miRNAs down-regulate HLA class I and II expression on the cell surface. HLA class II functions as a receptor for EBV entry into B cells. Specific HLA class II alleles correlate with the susceptibility of B cells to EBV infection in vitro and with EBV seropositivity or seronegativity of humans. HLA class I polymorphisms correlate with development and severity of EBV infectious mononucleosis and with the risk of several virus-associated malignancies including nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease.

Significance: These findings indicate that while EBV has evolved to use MHC class II as a receptor for virus entry, polymorphisms in MHC class II and class I influence virus infection and disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

爱泼斯坦-巴尔病毒与人类白细胞抗原复合物

目的:虽然大多数成年人感染eb病毒(EBV)，但仍有3-5%的人未被感染。控制许多病原体的人类白细胞抗原(HLA)复合物可能影响与EBV相关的感染和疾病。近期发现:大量EBV蛋白和mirna下调细胞表面HLA I类和II类的表达。HLA II类作为EBV进入B细胞的受体。特异性HLAⅱ类等位基因与体外B细胞对EBV感染的易感性以及人类EBV血清阳性或阴性相关。HLA I类多态性与EBV传染性单核细胞增多症的发展和严重程度以及几种病毒相关恶性肿瘤(包括鼻咽癌、霍奇金淋巴瘤和移植后淋巴细胞增生性疾病)的风险相关。意义:这些发现表明，虽然EBV已经进化到使用MHC II类作为病毒进入的受体，但MHC II类和MHC I类的多态性影响病毒感染和疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Clinical Microbiology Reports MICROBIOLOGY-

CiteScore

7.50

自引率

1.90%

发文量

期刊介绍： Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world’s foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.